Exploration of Cardiology

Table 6. Correlational analysis of demographic factors and therapeutic strategies, and survival in improved prognosis tumor types.

Variable	Type	Correlation	p-value
Tumor size (per mm)	Continuous	0.5044	0.0011
Age recode with <1 year old and 90+	Categorical	–0.1227	0.0206
Sex	Categorical	0.1013	0.0561
Race and origin recode (NHW, NHB, NHAIAN, NHAPI, Hispanic)	Categorical	–0.0521	0.3267
RX Summ—Surg Prim Site (1998+)	Categorical	–0.0009	0.9862
Radiation recode	Categorical	0.1174	0.0268
Chemotherapy recode (yes, no/unknown)	Categorical	–0.3372	0.0000
Median household income inflation-adjusted to 2022	Categorical	–0.0129	0.8078
Rural-urban continuum code	Categorical	0.0479	0.3679
ICD-O-3 Hist/behavior	Categorical	0.1924	0.0003
Cancer subtype	Categorical	0.1714	0.0012
SEER Combined Mets at DX-bone (2010+)	Categorical	0.1485	0.0050
SEER Combined Mets at DX-brain (2010+)	Categorical	0.1144	0.0309
SEER Combined Mets at DX-liver (2010+)	Categorical	0.1454	0.0060
SEER Combined Mets at DX-lung (2010+)	Categorical	0.1030	0.0522
Sequence number	Categorical	0.0980	0.0647

Return to article view

NHAIAN: non-Hispanic American Indian/Alaska Native; NHAPI: Non-Hispanic Asian/Pacific Islander; NHB: non-Hispanic Black; NHW: non-Hispanic Whites; SEER: Surveillance, Epidemiology, and End Results.

Supplementary materials

The supplementary table for this article is available at: https://www.explorationpub.com/uploads/Article/file/1012107_sup_1.xlsx.

Declarations

Acknowledgments

The authors would like to thank the University of Missouri-Kansas City School of Medicine for its academic support and scholarly resources.

Author contributions

RM: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Project administration, Supervision. ZM: Investigation, Data curation, Writing—original draft, Writing—review & editing. SK: Data curation, Formal analysis, Resources, Validation, Writing—original draft, Writing—review & editing. JJ: Writing—original draft, Writing—review & editing. TA: Supervision, Project administration. All authors read and approved the submitted version.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

This study utilized de-identified data from the publicly available Surveillance, Epidemiology, and End Results (SEER) Program database. As the dataset contains no identifiable patient information and involves no direct interaction with human participants, this study was considered exempt from Institutional Review Board review and the requirement for informed consent was waived, consistent with the ethical principles outlined in the Declaration of Helsinki.

Consent to participate

This study utilized de-identified data from the publicly available Surveillance, Epidemiology, and End Results (SEER) Program database. As the dataset contains no identifiable patient information and involves no direct interaction with human participants, the informed consent was waived, consistent with the ethical principles outlined in the Declaration of Helsinki.

Consent to publication

Informed consent was waived because this study used publicly available, de-identified data from the Surveillance, Epidemiology, and End Results (SEER) Program database, which contains anonymized cancer registry information collected for public health surveillance. No identifiable patient information was accessed.

Availability of data and materials

Data is publicly available and submitted with the manuscript as supplemental materials. The data analyzed in this study were obtained from the SEER database. Requests for access to these datasets should be directed to https://seer.cancer.gov/data/access.html.

Funding

This study was not supported by any sponsor or funder.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Garcia Brás P, Branco LM, Galrinho A, Timóteo AT, Branco Mano T, Ferreira V, et al. Malignant Primary and Metastatic Cardiac Tumors: A Single-Center 27-Year Case Review. Oncology. 2023;101:292–302. [DOI] [PubMed]

Oliveira GH, Al-Kindi SG, Hoimes C, Park SJ. Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of > 500 Patients. Circulation. 2015;132:2395–402. [DOI] [PubMed]

Chen X, Chen Y, Xiao F, Liu M, Gu Z, Li Y, et al. Survival and analysis of prognostic factors for primary malignant cardiac tumors based on the SEER database. J Cancer Res Clin Oncol. 2023;149:15687–96. [DOI] [PubMed] [PMC]

Maraj S, Pressman GS, Figueredo VM. Primary cardiac tumors. Int J Cardiol. 2009;133:152–6. [DOI] [PubMed]

Perchinsky MJ, Lichtenstein SV, Tyers GF. Primary cardiac tumors: forty years’ experience with 71 patients. Cancer. 1997;79:1809–15. [DOI] [PubMed]

Hudzik B, Miszalski-Jamka K, Glowacki J, Lekston A, Gierlotka M, Zembala M, et al. Malignant tumors of the heart. Cancer Epidemiol. 2015;39:665–72. [DOI] [PubMed]

Wang W, Kang L, Zhang J, Li H, Cao T, He S. Age and treatment disparities in survival of primary malignant cardiac tumors: an analysis of over 40 years and 500 patients. J Thorac Dis. 2023;15:4434–44. [DOI] [PubMed] [PMC]

SEER Incidence Data, 1975–2023 [Internet]. NIH and SEER; [cited 2025 Aug 23]. Available from: https://seer.cancer.gov/data/index.html

Javed Z, Haisum Maqsood M, Yahya T, Amin Z, Acquah I, Valero-Elizondo J, et al. Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2022;15:e007917. [DOI] [PubMed]

10.

Gordon MJ, Danilova O, Spurgeon S, Danilov AV. Cardiac non-Hodgkin’s lymphoma: clinical characteristics and trends in survival. Eur J Haematol. 2016;97:445–52. [DOI] [PubMed]

11.

Sun D, Wu Y, Liu Y, Yang J. Primary cardiac myxofibrosarcoma: case report, literature review and pooled analysis. BMC Cancer. 2018;18:512. [DOI] [PubMed] [PMC]

12.

Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-like lesions, and its incidences. Gen Thorac Cardiovasc Surg. 2013;61:435–47. [DOI] [PubMed] [PMC]

13.

Maleszewski JJ, Basso C, Bois MC, Glass C, Klarich KW, Leduc C, et al. The 2021 WHO Classification of Tumors of the Heart. J Thorac Oncol. 2022;17:510–8. [DOI] [PubMed]

14.

Heaton JN, Dhaduk N, Okoh AK, Dang-Ho KP, Tayal R, Salemi A, et al. Characteristics, management, and outcomes among admissions for primary cardiac tumors: Results from the National Inpatient Sample. J Card Surg. 2021;36:3586–92. [DOI] [PubMed]

15.

Cao J, Tan Z, Yang E, Ji Q, Fang M, Liu J. Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis. Cardiooncology. 2025;11:109. [DOI] [PubMed] [PMC]

16.

Ramlawi B, Leja MJ, Abu Saleh WK, Al Jabbari O, Benjamin R, Ravi V, et al. Surgical Treatment of Primary Cardiac Sarcomas: Review of a Single-Institution Experience. Ann Thorac Surg. 2016;101:698–702. [DOI] [PubMed]

17.

Blackmon SH, Reardon MJ. Surgical treatment of primary cardiac sarcomas. Tex Heart Inst J. 2009;36:451–2. [PubMed] [PMC]

18.

Carras S, Berger F, Chalabreysse L, Callet-Bauchut E, Cordier JF, Salles G, et al. Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series. Hematol Oncol. 2017;35:510–9. [DOI] [PubMed]

19.

Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. Radiographics. 2000;20:1073–103. [DOI] [PubMed]